Message from the President

Elaine Lim.JPG

Elaine LIM

Senior Consultant

National Cancer Centre, Singapore

Dear SSO Members,



I was recently reminded of the epic book ‘The Emperor of All Maladies’ by Siddhartha Mukherjee. The author had taken on the mammoth task of charting the significant historical events in oncology over a broad sweep of time – a riveting read. If ‘The Emperor of All Maladies Part II’ were to be written 100-1000 years from now, I do wonder how COVID-19’s impact on oncological care would be interpreted.


Living through COVID-19 times has shone the spotlight on the human immune system, Darwinian evolution by natural selection, global healthcare inequalities (resources, infrastructure, service provision), let alone how each and every one’s daily life has been changed. Endless squinting at computer/phone screens and interminable talking during video conferencing, tighter scheduling of meetings (because with Zoom, we can!), and continually breathing N95-filtered air have all led to poorer eyesight, parched throats/hoarse voices, heightened stress levels, and an indelible imprint of the N95 mask on our collective psyche – and face.

SSO was the first professional medical society in issuing a consensus statement in January 2021, regarding COVID-19 vaccination in cancer patients.


SSO Meetings/Events

Meeting attendance numbers soared. Greater accessibility is a clear advantage of virtual conferences; savings in carbon emissions is another (international air travel leaves a big environmental footprint). Networking, however, has taken a hit – this is a situation where in-person meetings are irreplaceable.


SSO’s list of virtual meetings grew over 2020-2021 – some were held in conjunction with other professional medical societies, local and international. The topics reflected the composition of SSO Membership, spanning the disciplines of Medical Oncology, Radiation Oncology, Surgical Oncology, Palliative Medicine. Meeting attendance saw robust participation from our colleagues from neighbouring countries.


The SSO Medical Oncology Review Course was a hit – again. The presentations were top-notch. The active participation by the audience was gratifying. Watching the exiting Senior Residents writhe in agony during the mock viva was akin to watching Squid Game – variably described as macabre and voyeuristic. Well Done to the Senior Residents who successfully exited in July 2021!


Instead of combining with Best of ASCO (BASCO), the SSO Annual Scientific Meeting 2021 was a standalone affair. Abstract submissions reached a record number. Needless to say, the overall quality of the presentations was excellent. Whether BASCO will be resumed in 2022 remains to be seen – we shall be keeping our ear to the ground.


ESMO Asia Congress 2021 was converted to ESMO Asia Virtual Oncology Week 2021. This covered ESMO highlights of the year, including special sessions on new practice-changing data. In the spirit of collaboration, SSO continued to participate in ESMO’s project on Pan-Asian Guidelines Adaptation (PAGA).


Healthcare Policy

There had been greater engagement between SSO and the Ministry of Health, specifically the Agency for Care Effectiveness (ACE), as regards national healthcare financing (MediShield Life [MSL] in cancer treatment) and other healthcare-related policy-making. In October 2020, SSO responded to MOH’s call for public consultation on MSL and its use/role in the future. A series of meetings ensued. In August 2021, it was announced that a more granular set of MSL claims criteria would come into effect in September 2022. The ‘positive list’ is a dynamic one, which ACE intends to update from the health economic / cost effectiveness standpoint, together with the generation of clinical data, preferably guided by clinical practice guidelines, such as the Singapore Cancer Network (SCAN) guidelines. This is an area that SSO aims to be involved in by partnering the guardian of the SCAN guidelines – the Chapter of Medical Oncologists of the Academy of Medicine, Singapore.


SSO wrote an op-ed on healthcare financing of cancer drugs, vis-à-vis MediShield Life and Singapore’s healthcare ecosystem, which was published in the Straits Times and LianHe ZaoBao in August 2021. There were also TV interviews on local news.


By virtue of being a professional medical society, consisting of clinicians from different specialties involved in the clinical care of cancer patients, SSO is keen to continue to lend its voice and share the clinician’s perspective in matters pertaining to cancer care in Singapore.


In Gratitude

The fact that SSO is able to achieve its objectives is due to the support it has received from multiple parties. Pharmaceutical companies and other industry partners are our steadfast allies in pushing our agenda in education and research. They have been instrumental in the sourcing of expert speakers, time-tabling and convening of meetings, and managing to remain cheerful and unfazed by doctors’ tardiness in response, grumpiness, and unexpected meeting interruptions by IT-related incidents. Other professional medical societies/bodies, such as ESMO, ASCO, and our regional sister oncology societies, have collaborated with SSO or participated in SSO events, and in so doing, demonstrated the strong professional bond of the international community of oncology doctors. Our Secretariat, Globewerks, has been working tirelessly in providing administrative support for SSO events and activities, as well as managing our website and social media presence.


SSO Members: Your participation in and feedback on the SSO events is invaluable. You are the sine qua non of SSO’s realising of its mission objectives.


To all who have supported SSO in all different ways: Thank You.


Best Wishes for 2022.


Elaine Lim


Singapore Society of Oncology